Brain+ CPSE:BRAINP Stock Report

Kim Arvid Nielsen Decides to Step Down from the Board of Brain+ A/S

Paula Petcu Joins Brain+ as New Chief Technology Officer

Paula Petcu joined Brain+ as new Chief Technology Officer after the company's IPO in 2021, and is now driving forth the company's product development work and technology platform initiatives. She came from Lundbeck A/S.

Brain+ A/S Announces Publication of Results from an Earlier Study That Showed Cognitive Improvements in People with Brain Injury After Training with Brain+ Recover Computerized Cognitive Training Product

Brain+ A/S announced Critical, early validation of Brain+ Computerized Cognitive Training technology as effective on specific cognitive outcomes relevant for patients with dementia. Cognitive problems are primary symptoms in pre-stages of dementia and often caused by Alzheimer's disease. Insights from this study have been built into both the design of Brain+' new dementia product, Cognitive Stimulation Therapy, and the next generation of cognitive training Brain+ is devoloping to target pre-stages of  dementia in Alzheimer's patients. A pilot study from 2019, testing the feasibility and effect of two different computerized cognitive training programs,including Recover from Brain+, has been published in the highly recognized Journal of Brain Injury. In the study, a total of 59 brain injury patients participated including the active and control groups. Fourteen brain injury patients trained for 12 weeks using the Brain+ Recover program, a 2019 version of the Brain+ Cognitive Training technology. The study findings provided a critical, early validation of Brain+ Cognitive Training technology as effective on specific cognitive outcomes relevant for patients with dementia. The study also provided valuable insights on the relevance of continuous support from health care professionals to help patients administer the training optimally and effectively. The study was carried out at The Center for Brain Injury by Katrine Svaerke, Jesper Mogensen, Frank Humle, Morten Tjørnlund and Sandra Pyke. Brain Injury is relevant to Brain+' dementia focus. Brain Injury imposes significant risk of conversion to dementia, and the specific working memory problems in Brain Injury, and the benefits reported from the Brain+ Cognitive Training are highly relevant to the cognitive issues observed in Alzheimer's and dementia. The purpose of the study was to test the feasibility and efficacy in people with brain injury in the chronic phase using two different cognitive training programs against a control group. The results showed that Brain+ Recover is feasible to use in patients with Brain Injury, and when administered with support from therapist, is effective on specific subcomponents of working memory. The effectiveness on these cognitive functions were unique to the Brain+ Recover Cognitive Training compared to the other conditions (control and other cognitive training program). The effects sustained at the six months follow up showing long term benefits of the training. There was no effect when patients trained without therapist support, indicating the important role of the therapist, and the need for developing support mechanisms to ensure motivation, compliance, and efficacy of the training.

Positive Results from the First of Four Clinical Studies to Evaluate Brain+' Starry Night Cognitive Test for Early Detection of Alzheimer's Disease

A study led by Professor Masud Husain, at the University of Oxford, has evaluated the feasibility and performance of the Starry Night cognitive test intended for early detection of Alzheimer's disease. The Starry Night test is developed by Brain+ as a gamified version of a lab-test, developed by Professor Husain's team and proven to be sufficiently sensitive to detect pre-symptomatic Alzheimer's disease. Alzheimer's disease can begin to create changes in the brain up to 20 years before symptoms are detected, at which point the disease has already caused significant cognitive impairment. If Alzheimer's can be detected at an earlier stage, it would allow more effective action to be taken, with either lifestyle interventions, traditional pharmaceuticals or digital therapeutics such as cognitive training - or a combination of all of these. The Oxford study of the Starry Night test had a total of 131 healthy participants of all adult ages, including people over the age of 50. The objective of the study was to evaluate the Brain+ Starry Night test against the original lab test by comparing test outcomes. The results showed that the critical test outcomes were comparable between the two tests, thus validating the feasibility of the Starry Night test. As a secondary result, the study showed that the Starry Night test can be successfully used by individuals without regular access to neurology clinics. This is important, since it demonstrates that the test is suitable for scalable remote testing in people's homes. The Starry Night test works on the well-described clinical findings that individuals at high risk of developing Alzheimer's dementia, but showing no apparent symptoms, exhibit a particular pattern of cognitive deficits related to memory and attention. The Starry Night test is designed as a game which builds on the thoroughly researched lab-test developed in Masud Husain's lab at Oxford University. The Starry Night test is designed to run on smartphones and tablets, so people can perform it from home, allowing scalable and remote testing. The Starry Night test has been developed as part of an EU-Horizon2020 funded innovation project led by Brain+ and with partners University of Oxford, Nottingham University, Aarhus University, Aarhus University Hospital, Alzheimer Europe and the European Brain Council. The total project budget is E3.5 million, and the project runs from November 2018 to April 2022. The main objective is to engage people early before Alzheimer's disease manifests to detect the disease to enable prevention efforts. The project focuses on enabling early presymptomatic detection of Alzheimer's Disease with a special memory test developed by the University of Oxford, which during the project has been further co-developed and gamified with Brain+. The test, called Starry Night, is being validated in four studies, two at University of Oxford, one at Nottingham University, and one at Aarhus University. A second work stream aims to reduce risk of Alzheimer's disease in healthy elderlies, who are at risk of Alzheimer's disease, via general cognitive training.

Brain+ A/S Appoints Bertil S. Jessen as Chief Financial Officer, Effective March 1, 2022

Brain+ A/S announced that Bertil S. Jessen will join Brain+ as the company's Chief Financial Officer on March 1, 2022. Bertil will add further key competences to the leadership team as he brings solid international business and corporate finance as well as strategic partnership experience. He joins Brain+ from a position as head of a global strategic business program in GN Store Nord and has previous experience from strategy and M&A advisory roles in Maersk and in J.P. Morgan's investment banking division.